Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 18-Apr-24 8:48 PM View:  | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 16-Apr-24 | Option Exercise | 1,750 | $7.60 | $13,295.00 | 101% 1.74K to 3.49K | |
| 18-Apr-24 8:48 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 16-Apr-24 | Planned Option Sale | 1,750 | $25.74 | $45,045.00 | (50%) 3.49K to 1.74K | |
| 03-Apr-24 7:18 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Apr-24 | Option Exercise | 8,153 | $12.54 | $102,224.00 | 469% 1.74K to 9.89K | |
| 03-Apr-24 7:18 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Apr-24 | Planned Option Sale | 8,153 | $31.78 | $259,102.00 | (82%) 9.89K to 1.74K | |
| 29-Mar-24 4:52 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 27-Mar-24 | Option Exercise | 5,833 | $25.98 | $151,541.00 | 336% 1.74K to 7.57K | |
| 29-Mar-24 4:52 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 27-Mar-24 | Planned Option Sale | 5,833 | $35.04 | $204,410.00 | (77%) 7.57K to 1.74K | |
| 20-Mar-24 4:40 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 18-Mar-24 | Option Exercise | 1,750 | $7.60 | $13,295.00 | 101% 1.74K to 3.49K | |
| 20-Mar-24 4:40 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 18-Mar-24 | Planned Option Sale | 1,750 | $31.27 | $54,722.50 | (50%) 3.49K to 1.74K | |
| 29-Feb-24 6:01 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 27-Feb-24 | Option Exercise | 1,909 | $20.24 | $38,638.20 | 110% 1.74K to 3.65K | (10%) |
| 29-Feb-24 6:01 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 27-Feb-24 | Planned Private Option Sale | 1,909 | $30.00 | $57,270.00 | (52%) 3.65K to 1.74K | |
| 21-Feb-24 5:41 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 16-Feb-24 | Option Exercise | 1,750 | $7.60 | $13,295.00 | 101% 1.74K to 3.49K | |
| 21-Feb-24 5:41 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 16-Feb-24 | Planned Option Sale | 1,750 | $27.67 | $48,422.50 | (50%) 3.49K to 1.74K | |
| 12-Feb-24 9:04 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 08-Feb-24 | Option Exercise | 6,244 | $10.18 | $63,586.20 | 359% 1.74K to 7.98K | |
| 12-Feb-24 9:04 PM View: | Bizily Scott Chief Legal Officer | 4d Molecular Therapeutics, ... (FDMT) | 08-Feb-24 | Planned Option Sale | 6,244 | $27.50 | $171,710.00 | (78%) 7.98K to 1.74K | |
| 12-Feb-24 8:22 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 08-Feb-24 | Private Sale (Planned) | 92,001 | $27.13 | $2,495,820.00 | (8%) 1.15M to 1.06M | |
| 07-Feb-24 8:32 PM View: | Kim Robert Young Chief Medical Officer | 4d Molecular Therapeutics, ... (FDMT) | 05-Feb-24 | Planned Option Sale | 24,000 | $30.05 | $721,200.00 | (94%) 25.59K to 1.59K | |
| 07-Feb-24 8:32 PM View: | Kim Robert Young Chief Medical Officer | 4d Molecular Therapeutics, ... (FDMT) | 05-Feb-24 | Sale (Planned) | 552 | $30.05 | $16,587.60 | (35%) 1.59K to 1.04K | |
| 07-Feb-24 8:32 PM View: | Kim Robert Young Chief Medical Officer | 4d Molecular Therapeutics, ... (FDMT) | 05-Feb-24 | Option Exercise | 24,000 | $15.28 | $366,840.00 | 1505% 1.59K to 25.59K | |
| 25-Jan-24 4:59 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 23-Jan-24 | Market Sale (Planned) | 5,696 | $18.41 | $104,851.00 | (< 1%) 1.16M to 1.15M | 1% |
| 08-Jan-24 4:19 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 05-Jan-24 | Sale (Planned) | 28,237 | $19.57 | $552,478.00 | (2%) 1.19M to 1.16M | |
| 05-Jan-24 5:44 PM View: | Viking Global Investors Lp 10% Owner | 4d Molecular Therapeutics, ... (FDMT) | 04-Jan-24 | Market Sale | 540,000 | $19.53 | $10,546,200.00 | (11%) 4.79M to 4.25M | 7% |
| 08-Jan-24 4:19 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 04-Jan-24 | Private Sale (Planned) | 40,732 | $20.31 | $827,202.00 | (3%) 1.23M to 1.19M | |
| 08-Jan-24 4:19 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 18-Dec-23 | Market Sale (Planned) | 4,702 | $18.13 | $85,242.60 | (< 1%) 1.23M to 1.23M | (< 1%) |
| 08-Jan-24 4:19 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 15-Dec-23 | Market Sale (Planned) | 28,632 | $17.27 | $494,432.00 | (2%) 1.26M to 1.23M | (5%) |
| 12-Jun-23 6:23 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 08-Jun-23 | Option Exercise | 3,750 | $8.04 | $30,150.00 | 216% 1.74K to 5.49K | |
| 12-Jun-23 6:23 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 08-Jun-23 | Planned Option Sale | 3,750 | $20.85 | $78,187.50 | (68%) 5.49K to 1.74K | |
| 16-May-23 8:52 PM View: | Moretti August J Chief Financial Officer | 4d Molecular Therapeutics, ... (FDMT) | 15-May-23 | Option Exercise | 3,000 | $9.41 | $28,230.00 | 37% 8.04K to 11.04K | |
| 11-May-23 5:50 PM View: | Viking Global Investors Lp 10% Owner | 4d Molecular Therapeutics, ... (FDMT) | 09-May-23 | Private Purchase | 850,000 | $16.00 | $13,600,000.00 | 22% 3.94M to 4.79M | |
| 04-May-23 10:00 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 02-May-23 | Gift | 600,000 | -- | -- | (24%) 2.46M to 1.86M | |
| 04-May-23 10:00 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 02-May-23 | Gift | 600,000 | -- | -- | 32% 1.86M to 2.46M | |
| 25-Apr-23 6:44 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 21-Apr-23 | Option Exercise | 3,750 | $8.04 | $30,150.00 | 178% 2.11K to 5.86K | |
| 25-Apr-23 6:43 PM View: | Chacko Jacob Director | 4d Molecular Therapeutics, ... (FDMT) | 21-Apr-23 | Planned Option Sale | 5,000 | $20.05 | $100,270.00 | (100%) 5.0K to 0 | |
| 25-Apr-23 6:44 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 21-Apr-23 | Planned Option Sale | 3,750 | $20.00 | $75,000.00 | (64%) 5.86K to 2.11K | |
| 25-Apr-23 6:43 PM View: | Chacko Jacob Director | 4d Molecular Therapeutics, ... (FDMT) | 21-Apr-23 | Option Exercise | 5,000 | $9.41 | $47,050.00 | 100% 0 to 5.0K | |
| 03-Mar-23 6:16 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Mar-23 | Planned Option Sale | 1,875 | $19.30 | $36,187.50 | (43%) 4.36K to 2.48K | |
| 03-Mar-23 6:16 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Mar-23 | Sale (Planned) | 373 | $19.30 | $7,198.90 | (15%) 2.48K to 2.11K | |
| 03-Mar-23 6:16 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Mar-23 | Option Exercise | 1,875 | $6.49 | $12,168.80 | 76% 2.48K to 4.36K | |
| 23-Feb-23 7:56 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 22-Feb-23 | Sale (Planned) | 16,449 | $20.22 | $332,665.00 | (< 1%) 1.88M to 1.86M | |
| 23-Feb-23 7:56 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 21-Feb-23 | Private Sale (Planned) | 17,997 | $20.96 | $377,209.00 | (< 1%) 1.89M to 1.88M | |
| 23-Jan-23 7:57 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 20-Jan-23 | Sale (Planned) | 8,625 | $20.19 | $174,127.00 | (< 1%) 1.9M to 1.89M | |
| 23-Jan-23 7:57 PM View: | Kirn David Chief Executive Officer Director | 4d Molecular Therapeutics, ... (FDMT) | 19-Jan-23 | Private Sale (Planned) | 10,899 | $20.03 | $218,347.00 | (< 1%) 1.91M to 1.9M | |
| 22-Dec-22 6:51 PM View: | Moretti August J Chief Financial Officer | 4d Molecular Therapeutics, ... (FDMT) | 21-Dec-22 | Option Exercise | 3,000 | $9.41 | $28,230.00 | 83% 3.6K to 6.59K | |
| 19-Dec-22 5:56 PM View: | Kirn David Chief Executive Officer Director 10% Owner | 4d Molecular Therapeutics, ... (FDMT) | 16-Dec-22 | Sale (Planned) | 53,944 | $23.02 | $1,241,580.00 | (3%) 1.97M to 1.91M | |
| 19-Dec-22 5:56 PM View: | Kirn David Chief Executive Officer Director 10% Owner | 4d Molecular Therapeutics, ... (FDMT) | 15-Dec-22 | Private Sale (Planned) | 32,933 | $23.59 | $776,767.00 | (2%) 2.0M to 1.97M | |
| 05-Dec-22 5:33 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Dec-22 | Option Exercise | 5,625 | $7.52 | $42,318.80 | 197% 2.86K to 8.48K | |
| 05-Dec-22 5:33 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Dec-22 | Planned Option Sale | 5,625 | $22.79 | $128,180.00 | (66%) 8.48K to 2.86K | |
| 05-Dec-22 5:33 PM View: | Bizily Scott Chief Legal and HR Officer | 4d Molecular Therapeutics, ... (FDMT) | 01-Dec-22 | Sale (Planned) | 375 | $22.79 | $8,545.31 | (13%) 2.86K to 2.48K | |
| 22-Oct-21 9:42 PM View: | Schaffer David Director | 4d Molecular Therapeutics, ... (FDMT) | 22-Oct-21 | Market Sale (Planned) | 1,900 | $31.00 | $58,892.80 | (< 1%) 903.12K to 901.22K | (2%) |
| 22-Oct-21 9:42 PM View: | Schaffer David Director | 4d Molecular Therapeutics, ... (FDMT) | 21-Oct-21 | Market Sale (Planned) | 22,820 | $31.56 | $720,156.00 | (2%) 925.93K to 903.12K | (< 1%) |
| 22-Oct-21 9:42 PM View: | Schaffer David Director | 4d Molecular Therapeutics, ... (FDMT) | 20-Oct-21 | Market Sale (Planned) | 11,565 | $31.02 | $358,771.00 | (1%) 937.5K to 925.93K | (2%) |
